PharmaShots | Incisive News in 3 Shots

Subscribe Now

Kymera Therapeutics

Kymera Therapeutics and Sanofi Report First Patient Dosing with KT-474 in P-II Trial for the Treatment of Atopic Dermatitis

Kymera Therapeutics and Sanofi Report First Patient Dosing with KT-474 in P-II Trial for the Treatment of Atopic Dermatitis

December 8, 2023

Kymera Therapeutics Receives the US FDA’s Fast Track Designation to KT-333 for Cutaneous and Peripheral T-Cell Lymphoma

Kymera Therapeutics Receives the US FDA’s Fast Track Designation to KT-333 for Cutaneous and Peripheral T-Cell Lymphoma

September 20, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us